Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

Share Price Information for Alliance Pharma (APH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.10
Bid: 32.95
Ask: 33.85
Change: -0.60 (-1.78%)
Spread: 0.90 (2.731%)
Open: 33.95
High: 33.95
Low: 32.95
Prev. Close: 33.70
APH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Share Dealing

12 Nov 2018 15:51

RNS Number : 1014H
Alliance Pharma PLC
12 November 2018
 

12 November 2018

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Director Share Dealing

Alliance Pharma plc (AIM: APH), the international specialty pharmaceutical group, announces that it was notified on 9 November 2018 that, on the same day, John Dawson, Non-Executive Director, sold 1,100,000 ordinary shares of 1 pence each in the Company at a price of 70.1 pence per share.

Following this transaction, Mr Dawson's total interest in the Company is 55,476,402 ordinary shares, representing approximately 10.71 per cent of the Company's current issued share capital (comprised of a total beneficial interest in 35,476,402 Ordinary Shares, representing 6.85 per cent of the issued share capital, and a total non-beneficial interest in 20,000,000 Ordinary Shares, representing 3.86 per cent of the issued share capital).

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Gemma Mostyn-Owen

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

Corporate Broking: James Black

 

Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / David Herring

 

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Mr John Dawson

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alliance Pharma plc

b)

Legal Entity Identifier

213800RYIWZA4Q5WPZ13

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1.0 pence each

 

 

 

ISIN: GB0031030819

b)

Nature of the transaction

Sale of shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price (p)

Volume(s)

70.1p

1,100,000

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

1,100,000 ordinary shares

70.1p

£770,720.01

f)

Date of the transaction

9 November 2018

g)

Place of the transaction

London Stock Exchange, AIM

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFKBDQPBDDFDD
Date   Source Headline
13th Sep 20177:00 amRNSInterim Results
6th Sep 20177:00 amRNSAppointment of Joint Corporate Broker
1st Aug 20177:00 amRNSNotification of Interim Results
28th Jul 20174:21 pmRNSUpdate on Diclectin
25th Jul 20175:40 pmRNSChanges to interests of a significant shareholder
25th Jul 20175:34 pmRNSChanges to interests of a significant shareholder
18th Jul 20177:00 amRNSHalf Year Trading Update
3rd Jul 20172:29 pmRNSChanges to interests of a significant shareholder
26th Jun 20175:31 pmRNSChanges to interests of a significant shareholder
22nd Jun 20175:22 pmRNSChanges to interests of a significant shareholder
21st Jun 20172:53 pmRNSApplication for block admission
19th Jun 20173:16 pmRNSChanges to interests of a significant shareholder
19th Jun 20172:37 pmRNSApplication for admission
14th Jun 20174:54 pmRNSApplication for admission
25th May 20173:20 pmRNSChanges to interests of a significant shareholder
25th May 201711:00 amRNSResult of AGM
25th May 20177:15 amRNSHardman Res.: Transformed International Business
25th May 20177:00 amRNSAGM Statement
22nd May 201710:10 amRNSApplication for admission
9th May 20171:50 pmRNSCorrection: Application for admission
8th May 20172:30 pmRNSApplication for admission
5th May 20176:10 pmRNSApplication for admission
5th May 20177:00 amRNSChanges to interests of a significant shareholder
5th May 20177:00 amRNSChanges to interests of a significant shareholder
4th May 20171:30 pmRNSChanges to interests of a significant shareholder
28th Apr 201712:15 pmRNSAnnual Report and AGM Notice
28th Apr 20179:45 amRNSChanges to interests of a significant shareholder
24th Apr 201711:33 amRNSChanges to interests of a significant shareholder
5th Apr 20171:30 pmRNSNotification of Major Interest in Shares
31st Mar 20174:59 pmRNSApplication for admission
29th Mar 20177:00 amRNSFull Year Results
21st Mar 20177:00 amRNSSettlement Agreement with Sinclair Pharma plc
2nd Mar 20177:00 amRNSNotification of Preliminary Results
14th Feb 20175:31 pmRNSPDMR shareholding
14th Feb 20175:30 pmRNSApplication for admission
7th Feb 20179:05 amRNSChanges to interests of a significant shareholder
31st Jan 20177:00 amRNSExercise of Share Options
25th Jan 20177:15 amRNSHardman Research: Potential of Diclectin
23rd Jan 20177:00 amRNSPre-Close Trading Update
16th Dec 20164:00 pmRNSExercise of Share Options
15th Dec 20164:50 pmRNSExercise of Share Options
12th Dec 20169:19 amRNSExercise of Share Options
9th Dec 201611:45 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
8th Dec 20167:00 amRNSCapital Markets Event
30th Nov 20164:00 pmRNSNotification of Major Interest in Shares
23rd Nov 20165:45 pmRNSExercise of Share Options
17th Nov 20165:05 pmRNSNotification of Major Interest in Shares
17th Nov 201610:40 amRNSExercise of Share Options
28th Oct 20165:13 pmRNSShare Options
28th Oct 20167:00 amRNSAppointment of Deputy CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.